Imagine a broken bridge between a control center and a machine; the signals just can't get through. This technology builds a digital bypass that reads the brain's 'move' command and sends it directly to the spinal cord. It's like installing a wireless router in the body to reconnect the brain to the limbs.
Spinal cord injuries cause permanent paralysis with no approved therapies, leading to massive lifelong care costs and loss of independence for patients.
Two fully-implantable brain-spine interface (BSI) systems: one for upper-limb function and one for walking, combining wireless neurosensors with a spinal stimulation platform.
If you are a neuroprosthetics developer dealing with the lack of approved SCI therapies — this project developed fully-implantable BSI systems that translate brain signals into spinal stimulation. This allows for the creation of commercial-grade devices for upper and lower limb recovery.
If you are a rehabilitation clinic dealing with lifelong care costs exceeding €2.5 million per patient — this project developed a system to restore walking and arm function. This reduces the long-term economic burden on healthcare systems and families.
If you are a neural interface startup dealing with low-precision brain recording — this project developed WIMAGINE, a high-density wireless neurosensor. This provides a technical foundation for high-precision cortical activity monitoring in humans.
The costs of lifelong care for a person with spinal cord injury exceed €2.5 million per person.
The project focused on generating industrial specifications for next-generation devices based on clinical trial results to open the path to a commercially-viable version.
The project integrates two breakthrough technologies: WIMAGINE (wireless implantable neurosensor) and ARC-IM (neurostimulation platform for movement recovery).
The project includes small scale clinical trials to assess safety, performance, and usability to support clinical translation.
The project period runs from 2022-05-01 to 2025-04-30.
The consortium is highly industry-oriented with a 50% industry ratio, consisting of 6 partners across 4 countries. With 3 SMEs involved and a mix of university and research entities, the group is structured to bridge the gap between academic research (ERC grants) and commercial medical device production.
Contact Onward Medical NV in the Netherlands
Contact us to explore licensing opportunities for WIMAGINE and ARC-IM technologies.
